Scarica l'app Stockscreener
51.48
3.69%
1.655
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha
Victory Capital Management Inc. Has $10.98 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN
MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: biopharma stock faces HS market potential, execution risks - Investing.com Canada
(MLTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics announces first patients screened in IZAR program - TipRanks
MoonLake Launches Major Phase 3 Trials for Psoriatic Arthritis Drug After Strong Phase 2 Results | MLTX Stock News - StockTitan
FMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics S - GuruFocus.com
MoonLake Immunotherapeutics (MLTX) Quarterly 10-Q Report - Quartzy
MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Q3 Earnings Forecast for MLTX Issued By Wedbush - Defense World
What is Wedbush's Forecast for MLTX Q3 Earnings? - MarketBeat
MoonLake Immunotherapeutics reports Q3 EPS (56c), consensus (43c) - TipRanks
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Strong-Buy" at Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
AlphaCentric Advisors LLC Invests $706,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
75,469 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Rice Hall James & Associates LLC - MarketBeat
MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN
I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St
(MLTX) Proactive Strategies - Stock Traders Daily
HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha
When (MLTX) Moves Investors should Listen - Stock Traders Daily
MoonLake Immunotherapeutics [MLTX] stock for 100,003,200 USD was sold by BVF PARTNERS L P/IL - Knox Daily
MLTX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing MoonLake Immunotherapeutics (MLTX)’s Performance - The Dwinnex
What is MLTX’s price-to-sales ratio telling us about the company’s value? - US Post News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down on Insider Selling - Defense World
Millennium Management LLC Has $9.54 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Biotechnology value fund L P executives sell over $100 million in MoonLake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics director sells shares worth over $9m - Investing.com
Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 171,000 Shares of Stock - Defense World
Simon Sturge Sells 171,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
MoonLake Immunotherapeutics director sells shares worth over $9m By Investing.com - Investing.com UK
Director Simon Sturge Sells 171,000 Shares of MoonLake Immunothe - GuruFocus.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 8.3%Here's What Happened - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Position Increased by The Manufacturers Life Insurance Company - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
MLTX’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How the (MLTX) price action is used to our Advantage - Stock Traders Daily
MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid clinical trials - Investing.com
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):